Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply

This publication has 8 references indexed in Scilit:

• Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection
  Alimentary Pharmacology & Therapeutics, 2026
• Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study
  Alimentary Pharmacology & Therapeutics, 2025
• Fecal microbiota transplantation: a tale of two regulatory pathways
  Gut Microbes, 2025
• Early geriatric assessment and management in older patients with Clostridioides difficile infection in Denmark (CLODIfrail): a randomised trial
  The Lancet Healthy Longevity, 2024
• Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials
  Frontiers in Pharmacology, 2024
• Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility
  Clinical Gastroenterology and Hepatology, 2024
• Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study
  Cells, 2022
• Randomised clinical trial: a 12‐strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections
  Alimentary Pharmacology & Therapeutics, 2021